Season 2 - Ep. 3: Arrhythmogenic mitral valve prolapse - Peripartum cardiomyopathy

Oct 26, 2023

Ask episode

Chapters

Transcript

Episode notes

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly.

This episode covers:

Cardiology This Week: A concise summary of recent studies

Peripartum cardiomyopathy

Arrhythmogenic mitral valve prolapse

Statistics Made Easy: The ‘Win Ratio’

Host: Perry Elliott

Guests: Carlos Aguiar, Johann Bauersachs and Kristina Haugaa

Want to watch that episode? Go to: https://esc365.escardio.org/event/1138

Disclaimer

This programme is intended for health care professionals only and is to be used for educational purposes.

The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.

Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.

Declarations of interests

Stephan Achenbach, Kristina Haugaa and Nicolle Kraenkel have declared to have no potential conflicts of interest to report.

Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede.

Johann Bauersachs has declared to have potential conflicts of interest to report: direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. by Roche Diagnostics (Acute Heart Failure), Pfizer (Atrial Fibrillation), Bristol Myers Squibb (Atrial Fibrillation), Bayer (Chronic Heart Failure), Boehringer-Ingelheim (Chronic Heart Failure), Novartis (Chronic Heart Failure), CVRx (Chronic Heart Failure), AstraZeneca (Chronic Heart Failure), Cardior (Chronic Heart Failure), Norgine (Chronic Heart Failure). Research funding from healthcare industry under your direct/personal responsibility (to department or institution): Roche Diagnostics (Atrial fibrillation, co-investigator), Norgine (heart failure / iron deficiency, principal investigator), Zoll Medical (heart failure, co-investigator), CVRx (heart failure, investigator).

Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Novo Nordisk, Terumo, Medtronic.

Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics.

Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.